Regenerating muscle

Celogos S.A. is applying its autologous cell therapy technology to treat incontinence by growing muscle precursor cells in vitro and re-implanting them. Last month, the company started the efficacy portion of a Phase II/III trial in urinary incontinence.

Because muscle does not regenerate on its own, incontinence is a common problem for people who undergo certain types of surgery or go through childbirth. Celogos (Paris, France) estimates that there are 50-100 million urinary incontinence patients in the U.S., the EU and Japan. Estimates are less clear for anal incontinence, but Celogos thinks there are about one-tenth the number of urinary incontinence cases. ...